Epigenetic remodeling of downstream enhancer regions is linked to selective expression of the IL1F10 gene in differentiated human keratinocytes

Talabot-Ayer, Dominique; Díaz-Barreiro, Alejandro; M, Ali; Palmer, Gaby

doi:10.1016/j.gene.2022.146800

Cited by 1 publication

(1 citation statement)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Due to chemokine production, keratinocytes recruit other immune cells in the lesional sites, including dendritic cells, mast cells, eosinophils, and T cells [30,31]. Keratinocytes produce a cascade of pro-inflammatory factors, including thymic stromal lymphopoietin (TSLP), TNF-α, IL-1, IL-6, IL-8, IL-18, IL-23, IL-33, IL-36, as well as anti-inflammatory IL-38, which takes part in keratinocyte differentiation and counteracts the pro-inflammatory effect of IL-36 [30,[32][33][34][35]. Exposure to Staphylococcus aureus, which typically dominates the microbiota of AD lesions, was demonstrated as one of the factors upregulating IL-36 with subsequent allergic reaction and increased synthesis of IL-4, IL-13, and IgE [36].…”

Section: Other Immunocompetent Cells Secreting Interleukinsmentioning

confidence: 99%

Immunopathogenesis of Atopic Dermatitis: Focus on Interleukins as Disease Drivers and Therapeutic Targets for Novel Treatments

Makowska

Nowaczyk

Blicharz

et al. 2023

IJMS

View full text Add to dashboard Cite

Atopic dermatitis is a chronic, recurrent inflammatory skin disorder manifesting by eczematous lesions and intense pruritus. Atopic dermatitis develops primarily as a result of an epidermal barrier defect and immunological imbalance. Advances in understanding these pathogenetic hallmarks, and particularly the complex role of interleukins as atopic dermatitis drivers, resulted in achieving significant therapeutic breakthroughs. Novel medications involve monoclonal antibodies specifically blocking the function of selected interleukins and small molecules such as Janus kinase inhibitors limiting downstream signaling to reduce the expression of a wider array of proinflammatory factors. Nevertheless, a subset of patients remains refractory to those treatments, highlighting the complexity of atopic dermatitis immunopathogenesis in different populations. In this review, we address the immunological heterogeneity of atopic dermatitis endotypes and phenotypes and present novel interleukin-oriented therapies for this disease.

show abstract